drugset / Trial / NCT00255567

Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis

NCT00255567 ↗

Phase 3 Completed 1142 enrolled Drugs for Neglected Diseases
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy and safety of SSG 30 days alone, PM 21 days alone and SSG and PM as a combination course of 17 days in the treatment of patients with VL.

Timeline

Start
2004-11
Primary completion
2010-01
Completion
2010-01

Outcome

Mixed primary results

paper The efficacy of PM was significantly lower than SSG (84.3% versus 94.1%, difference = 9.7%, 95% confidence interval, CI: 3.6 to 15.7%, p = 0.002). PMID 22724029 ↗

paper The efficacy of SSG & PM was comparable to SSG (91.4% versus 93.9%, difference = 2.5%, 95% CI: -1.3 to 6.3%, p = 0.198). PMID 22724029 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Paromomycin Small molecule 15 mg/kg —
Subject Paromomycin Small molecule 20 mg/kg —
Comparator sodium stibogluconate Unknown 20 mg/kg —